Psychiatric Multi-omics and Neuroimaging Project

Launched by MINGJUN ZHONG · Aug 29, 2024

Keywords

ClinConnect Summary

The Psychiatric Multi-omics and Neuroimaging Project is a clinical trial that aims to better understand how the brain's structure and function relate to gene activity in people with schizophrenia. The study will look at patients who have been diagnosed with mental disorders and compare them to healthy individuals. Participants will be asked to take their prescribed medication regularly for one year and will undergo assessments at the beginning and end of the study to track their progress.

To be eligible for this trial, participants need to be between 13 and 35 years old and should have been diagnosed with their condition within the last two years. The study is particularly interested in patients who have not yet taken medication or have only used it for a short period. It's important to note that individuals with a family history of severe mental illnesses, substance abuse, or serious physical health issues will not be able to participate. If you take part in this study, you can expect regular check-ups and monitoring to help researchers learn more about how mental disorders affect the brain and genetics.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
• • Course of disease: \<24 months
• • Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks
• • No nuclear magnetic contraindications.
• Exclusion Criteria:
• • Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
• • Have a major physical disease or infectious disease
• • History of coma and serious neurological disease 4.MRI contraindications.